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CASE PRESENTATION

A

79-year-old previously healthy woman presented
to her primary care physician with an 8-week history of non-pruritic, erythematous macules coalescing into patches on the trunk and extremities (Fig. 1).
Rash was not improving with steroid cream. She
described chills but no other B-symptoms. Further evaluation by a punch biopsy showed dermal inﬁltrate of atypical hematolymphoid cells (Fig. 2). Immunohistochemical
studies performed demonstrated that the cells of interest
are positive for CD33, CD4, CD56, CD123 and lysozyme.
The morphologic and immunophenotypic ﬁndings of the
cutaneous lesions were consistent with myeloid sarcoma, which can be a rare initial presentation of acute
myeloid leukemia (AML). The patient was directed to a
hospital for further evaluation for a hematologic malignancy. Upon arrival, the patient had stable vital signs
and a diffuse, non-tender, non-pruritic, maculopapular
rash noted on the anterior chest, extending towards the
neck and across the abdominal region. Admission labs
were signiﬁcant for leukocytosis and acute kidney injury
garnering the patient high risk for tumor lysis syndrome.

She was given one dose of rasburicase and started on
allopurinol. Peripheral blood smear showed left shifted
granulocytic maturation and dysplasia and up to 17%
blasts. Bone marrow biopsy revealed up to 78% blasts
consistent with AML. She was started on decitabine and
venetoclax. The patient was eventually discharged on
prophylactic medication and followed up with her hematologist. Despite close follow up, the patient decompensated a few months after initial therapy and unfortunately
died.
This is a rare case of AML diagnosed by skin biopsy.
Myeloid sarcoma is a rare isolated extramedullary leukemic tumor and should prompt cytogenic analysis for
prognostication and targeted treatment. Myeloid sarcoma can present in four different ways: de novo in the
absence of myelodysplasia, concurrently with AML,
representation of blast crisis or blast transformation in
myleoproliferative disorder and relapse of AML.1 The
prevalence of myeloid sarcoma is reported in 2−8%
of patients with AML.2 It is often misdiagnosed for
lymphoma, undifferentiated cancers and malignant
melanoma. The use of immunohistochemistry and
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immunophenotyping are crucial for accurate diagnosis of
myeloid sarcoma.2 The presentation of myeloid sarcoma
is variable and independent of age ranging from infants to
elderly. It manifests in 15−35% of AML cases at the time
of diagnosis.1 It occurs after the diagnosis of AML in up to
50% of cases.1 Additionally, it can appear as the initial
ﬁnding of relapsed AML.1 Regarding prognosis, literature
reports that patients with myeloid sarcoma due to AML
have worse outcomes than de novo myeloid sarcoma.2,3
Treatment for myeloid sarcoma is indistinguishable to

e52

AML with induction chemotherapy, usually a combination
of an anthracycline and cytarabine.3
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